Drug intelligence / Profile preview

BRL-501

Development stage: Preclinical
Lead developer: BRL Medicine
Modality: Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

BRL-501 is an investigational anti-PSMA (prostate-specific membrane antigen) chimeric antigen receptor T-cell (CAR-T) therapy under development by BRL Medicine. It is designed to target and eliminate PSMA-positive tumor cells, which are commonly found in prostate cancer. As a cell therapy, BRL-501 genetically engineers autologous T cells to express a CAR specific for PSMA, enabling the immune system to better recognize and attack cancer cells. It is being developed primarily for the treatment of prostatic cancer and is currently in clinical development, with its highest phase of development reported as clinical.

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on BRL-501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRL-501.

Explore the full profile